Daxor Corporation (NASDAQ:DXR) Stock Short Interest Falls 69.7%

Daxor Corporation (NASDAQ:DXR) was the target of a significant decline in short interest in October. As of October 30th, there was short interest totaling 1,022 shares, a decline of 69.7% from the October 15th total of 3,374 shares. Based on an average trading volume of 11,538 shares, the days-to-cover ratio is presently 0.1 days. Currently, 0.0% of the company’s stock are sold short.

Daxor Trading Down 0.4%

DXR stock traded down $0.03 during trading on Friday, reaching $8.43. 16,805 shares of the company’s stock were exchanged, compared to its average volume of 11,660. The company’s fifty day moving average price is $10.14 and its 200-day moving average price is $10.55. Daxor has a 1-year low of $8.24 and a 1-year high of $14.76.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded Daxor from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Daxor has a consensus rating of “Moderate Buy”.

Institutional Trading of Daxor

Hedge funds and other institutional investors have recently modified their holdings of the company. Crescent Grove Advisors LLC bought a new position in shares of Daxor during the 1st quarter valued at about $104,000. Empirical Financial Services LLC d.b.a. Empirical Wealth Management purchased a new position in shares of Daxor during the first quarter valued at $245,000. Susquehanna International Group LLP grew its stake in Daxor by 97.7% during the 2nd quarter. Susquehanna International Group LLP now owns 27,131 shares of the company’s stock valued at $275,000 after acquiring an additional 13,411 shares in the last quarter. Finally, Aristides Capital LLC acquired a new position in Daxor in the 1st quarter valued at approximately $403,000. Institutional investors own 1.34% of the company’s stock.

About Daxor

Daxor Corporation (NASDAQ: DXR) is a medical device and biotechnology company focused on blood-volume measurement and related diagnostic applications. Its primary product is the BVA-100 Blood Volume Analyzer, a system designed to measure a patient’s total blood volume, plasma volume, red blood cell volume and hematocrit. The BVA-100 uses a blood sample and an iodine-131-labeled albumin tracer to provide quantitative blood-volume measurements. The technology is intended to support clinical assessment and management in areas including heart failure, critical care, kidney disease, blood disorders and perioperative care, where accurate information about a patient’s fluid and blood-volume status can assist treatment decisions.